Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX)
Health Care · Pharmaceuticals · US
$84.79
+0.12% today · +173.9% 1Y
Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.98B and employs 594 people.
Over the last twelve months the share price has gained 173.9%, trading between 28.73 and 84.76.
Tweenvest scores Crinetics Pharmaceuticals, Inc. across four factors: quality 29/100, value 78/100, growth 100/100. Its strongest factor is growth.
CRNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.98B
- Revenue (TTM)
- $42.16M
- P/E
- —
- EPS
- -5.03
- Dividend yield
- —
- Beta (5Y)
- 0.09
- 52-week high
- $84.76
- 52-week low
- $28.73
- Avg volume (3M)
- —
- Shares outstanding
- 106.07M
- Employees
- 594
- Next earnings
- —
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
- ISIN
- US22663K1079
- Founded
- 2008
- Listed since
- Jul 18, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,239.69 | -1.25% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.54 | +0.48% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $149.86 | -1.76% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.88 | -0.68% |
Figures last refreshed Aug 18, 2026.